Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics director Samantha Truex exercised restricted stock units into common shares. On March 28, the vesting and exercise of 3,166 restricted stock units at $0.00 per unit delivered 3,166 shares of common stock, bringing her direct common stock holdings to 6,333 shares.

These units are part of a grant of 9,500 restricted stock units awarded on August 13, 2024, which vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on her continued service.

Insider Trade Summary

3,166 shares exercised/converted

Mixed 2 txns

Insider Truex Samantha

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,166	$0.00	--
Exercise	Common Stock	3,166	$0.00	--

Holdings After Transaction: Restricted Stock Units — 3,167 shares (Direct); Common Stock — 6,333 shares (Direct)

Footnotes (1)

Restricted stock units convert into common stock on a one-for-one basis. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Key Figures

RSUs exercised: 3,166 units Exercise price: $0.00 per share Common shares after: 6,333 shares +1 more

4 metrics

RSUs exercised 3,166 units Restricted stock units converting to common stock on March 28, 2026

Exercise price $0.00 per share Conversion price for restricted stock units

Common shares after 6,333 shares Direct common stock holdings following RSU conversion

Total RSU grant 9,500 units Grant dated August 13, 2024, vesting in three equal tranches

Key Terms

Restricted Stock Units, one-for-one basis, vesting, continued service

4 terms

Restricted Stock Units financial

"Restricted Stock Units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

one-for-one basis financial

"Restricted stock units convert into common stock on a one-for-one basis."

vesting financial

"vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"subject to the Reporting Person's continued service on such vesting date."

Form 4 Insider Transactions: What Each Field Means →

03/31/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Truex Samantha

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/28/2026		M		3,166	A	⁽¹⁾	6,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/28/2026		M			3,166	⁽²⁾	⁽²⁾	Common Stock	3,166	$0	3,167	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Avalo Therapeutics (AVTX) director Samantha Truex report in this Form 4?

Samantha Truex reported the vesting and exercise of 3,166 restricted stock units into common stock. The transaction was recorded at $0.00 per share, reflecting a compensation-related equity award rather than an open-market purchase or sale of Avalo Therapeutics stock.

How many Avalo Therapeutics (AVTX) shares does Samantha Truex now hold directly?

Following the restricted stock unit conversion, Samantha Truex directly holds 6,333 shares of Avalo Therapeutics common stock. This increase comes from 3,166 shares delivered upon exercise of vested restricted stock units as part of her previously granted equity compensation package.

What equity award underlies the 3,166 Avalo Therapeutics (AVTX) shares acquired?

The 3,166 shares stem from a grant of 9,500 restricted stock units awarded on August 13, 2024. That grant vests in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, subject to Samantha Truex’s continued service with the company.

Were the Avalo Therapeutics (AVTX) shares in this Form 4 bought or sold on the market?

The shares were not bought or sold on the open market. Instead, they were issued at a conversion price of $0.00 per share when restricted stock units vested and converted into common stock, reflecting standard equity compensation mechanics for a company director.

What is the vesting schedule for Samantha Truex’s Avalo Therapeutics (AVTX) restricted stock units?

Her grant of 9,500 restricted stock units vests in three equal tranches. One-third vests on March 28, 2025, another third on March 28, 2026, and the final third on March 28, 2027, conditioned on her continued service on each vesting date.